Home » Clinical Trials »  Search Clinical Trials

Therapeutic Areas:  |  Endocrinology  |  Family Medicine

Search Medical Condition
Please enter condition
Please choose location
Clear Trial Filters

Diabetes Mellitus, Type 1 Clinical Trials

A listing of Diabetes Mellitus, Type 1 medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.


Found (22) clinical trials

Empagliflozin and ACEi Effects on Hyperfiltration in Type 1 Diabetes (BETWEEN Study)

This is a randomized, double-blind, double-dummy, placebo-controlled, cross over design trial with empagliflozin compared to placebo that is added to open-label ramipril in patients with type 1 diabetes.


Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) Versus GLP-1 Receptor Agonist in Patients With Type 2 Diabetes With a FRC Extension Period

The maximum duration for GLP1-RA patients will be approximately 29 weeks: an up to 2 week screening period, a 26 week treatment period (either randomized or uncontrolled), and a 3 or 9 day post-treatment safety followup period. Maximum duration for FRC patients will be approximately 55 weeks: an up to ...


Gan & Lee Insulin Glargine Target Type (1) Evaluating Research

Primary Objective: To demonstrate equivalence of Gan & Lee Pharmaceuticals insulin glargine and Lantus in terms of immunogenicity and efficacy Secondary Objectives: Immunogenicity: To evaluate the percentage of subjects with negative anti-insulin antibodies (AIA) at baseline who develop confirmed positive AIA up to Week 26


Repository of Novel Analytes Leading to Autoimmune Inflammatory and Diabetic Nephropathies (RENAL AID)

RENAL AID is designed as an inclusive data and tissue repository that is capable of linking demographic, clinical, laboratory, histology, genetic and radiographic data into one interconnected electronic data collection instrument. It is hypothesized that by linking these typically disconnected data components into a single electronic repository, RENAL AID will ...

Phase N/A

Assessment of Mealtime Bolus Insulin Behavior

The main purpose of this study is to estimate missed bolus insulin doses in diabetics. This is a 12-week, single-arm, outpatient, exploratory study with two study periods in Type 1 or Type 2 diabetics, with an investigational reusable injection pen, insulin, and a Continuous Glucose Monitoring (CGM) device.

Phase N/A

Research Study Comparing Insulin Degludec to Insulin Detemir Together With Insulin Aspart in Pregnant Women With Type 1 Diabetes

The investigators are doing this study to see the effect of insulin degludec in pregnant women with type 1 diabetes, and if it is safe to use. In this study the medicine insulin degludec is compared to another medicine called insulin detemir. Participants will either get insulin degludec or insulin ...


Single Ascending Dose Study of MK-1092 in Healthy Participants and in Participants With Type 1 and Type 2 Diabetes Mellitus (MK-1092-001)

There will be 4 parts in this study. In Part 1, healthy adult participants will be randomized to receive blinded MK-1092 subcutaneously (SC) or glargine SC, as a single dose under the euglycemic clamp. Once a safe and tolerated dose that achieves GIRmax is identified in Part 1, Part 2 ...


A Study to Evaluate Safety and Effects of Sotagliflozin Dose 1 and Dose 2 on Glucose Control in Patients With Type 2 Diabetes Severe Impairment of Kidney Function and Inadequate Blood Sugar Control

The study duration is up to 60 weeks including 4 weeks prior to randomization, 52 weeks of randomized treatment and a visit 4 weeks after completion of the randomized treatment period.


Evaluation of Virtual Versus Traditional Study Conducted in a Group Pilot Study in Adult Patients With Type 1 Diabetes Mellitus (eStudy)

The study will have a maximum study duration of 29 weeks, which consists of a 3-week screening period (including a possible 1-week delay in first IMP administration after randomization in virtual group due to shipment of IMP and the virtual devices), a 24-week treatment period, and a 2-day post-treatment safety ...


Liraglutide as an Additional Treatment to Insulin in Patients With Autoimmune Diabetes Mellitus

Autoimmune Diabetes Mellitus (AIDM) is a subtype of diabetes mellitus caused by autoimmune destruction of beta cells in the islet, including Type 1 diabetes and Latent Autoimmune Diabetes in Adults (LADA). Insulin has been used as a routine therapy for AIDM to alleviate the hyperglycemic status, yet cannot effectively prevent ...